Investor Presentaiton
SELECT TRIALS - EARLY PHASE ONCOLOGY
Lilly
Molecule
Study
Indication*
Title
Phase Patients
Primary Outcome**
Primary
Completion
Completion
Carcinoma,
KRAS G12C1 NCT04956640 Non-Small-
Study of LY3537982 in Cancer Patients With a
Specific Genetic Mutation (KRAS G12C)
1
400
Phase 1a: To determine the recommended phase 2
dose (RP2D) of LY3537982 monotherapy
Sep 2025 Sep 2025
Cell Lung
PI3K Selective NCT05307705
Breast
Cancer
A Study of LOXO-783 in Patients With Breast
Cancer/Other Solid Tumors (PIKASSO-01)
1
400
Phase 1a: To determine the MTD/RP2D of LOXO-783:|
Number of patients with dose-limiting toxicities
(DLTs)
May 2025 May 2025
FGFR3
Selective
RET Inhibitor
||
Urinary
NCT05614739 Bladder
Neoplasms
Carcinoma,
NCT05241834 Non-Small-
Cell Lung
A Study of LOXO-435 in Patients With Cancer With a
Change in a Gene Called FGFR3
1
140
Phase 1a: To determine the maximum tolerated
dose/recommended phase 2 dose (MTD/RP2D) of
LOXO-435: Number of patients with dose-limiting
toxicities (DLTs)
Jun 2025 Jun 2025
A Study of LOXO-260 in Cancer Patients With a
Change in a Particular Gene (RET) That Has Not
Responded to Treatment
1
110
Phase 1a: To determine the MTD/RP2D of LOXO-260:
Dose limiting toxicity (DLT) rate
Apr 2026 Apr 2026
Also lists Merck Sharp & Dohme LLC
* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes
Not for promotional use
Source: clinicaltrials.gov, July 21, 2023
2023 Q2 EARNINGS
56View entire presentation